Skip to main content
SpringerLink
Log in

Psychiatrists’ Attitudes Toward Non-Pharmacologic Factors Within the Context of Antidepressant Pharmacotherapy

  • Empirical Report
  • Published:
Academic Psychiatry Aims and scope Submit manuscript

Abstract

Objective

Recent meta-analyses of antidepressant clinical trials have suggested that up to 82 % of response can be attributed to non-medication-related factors. The present study examines psychiatrists’ attitudes regarding non-pharmacologic factors within the context of antidepressant pharmacotherapy.

Methods

A web-based, 20-question cross-sectional survey was distributed to 101 staff psychiatrists and 48 post-graduate trainees in psychiatry at an academic hospital in Boston, MA. Demographics, practice characteristics, beliefs about non-pharmacologic factors affecting prescribing practices, perceived response and remission rates, and opinions about the need for further investigations in the psychopharmacology process were assessed.

Results

Overall completion rate was 53 %. The final sample included 79 responses. The medians for clinician-perceived response rates (54 %) and remission rates (33 %) were in agreement with published rates. The reported median of the what portion of clinical outcomes is believed to be due to placebo effects (26 %) was numerically lower than suggested by literature. The contribution of the active ingredients of medications was perceived to be significantly higher than the contribution of patient characteristics and clinician characteristics. A longer time since graduation from medical school was significantly associated with higher belief in the effect of the active ingredients of antidepressant medications and with less perceived importance of placebo effects.

Conclusion

These findings suggest a discrepancy between empirical evidence and psychiatrists’ beliefs on the impact of placebo effects on clinical outcomes. Educating antidepressant prescribers about the evidence based on psychosocial mediators of placebo effects’ contribution to outcome may represent a promising strategy for improving clinical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–96.

    Article  PubMed  Google Scholar 

  2. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.

    Article  PubMed  Google Scholar 

  3. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry. 2006;67(11):1741–6.

    Article  CAS  PubMed  Google Scholar 

  4. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009;118(1–3):1–8.

    Article  CAS  PubMed  Google Scholar 

  5. Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the food and drug administration database. Arch Gen Psychiatry. 2000;57(4):311–7.

    Article  CAS  PubMed  Google Scholar 

  6. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252–60.

    Article  CAS  PubMed  Google Scholar 

  7. Clever SL, Ford DE, Rubenstein LV, Rost KM, Meredith LS, Sherbourne CD, et al. Primary care patients’ involvement in decision-making is associated with improvement in depression. Med Care. 2006;44:398–405.

    Article  PubMed  Google Scholar 

  8. Loh A, Simon D, Wills CE, Kriston L, Niebling W, Harter M. The effects of a shared decision-making intervention in primary care of depression: a cluster-randomized controlled trial. Patient Educ Couns. 2007;67(3):324–32.

    Article  PubMed  Google Scholar 

  9. Bensing JM, Verheul W. The silent healer: the role of communication in placebo effects. Patient Educ Couns. 2010;80(3):293–9.

    Article  PubMed  Google Scholar 

  10. Verheul W, Sanders A, Bensing J. The effects of physicians’ affect-oriented communication style and raising expectations on analogue patients’ anxiety, affect and expectancies. Patient Educ Couns. 2010;80(3):300–6.

    Article  PubMed  Google Scholar 

  11. Klein DN, Schwartz JE, Santiago NJ, Vivian D, Vocisano C, Castonguay LG, et al. Therapeutic alliance in depression treatment: controlling for prior change and patient characteristics. J Consult Clin Psychol. 2003;71(6):997–1006.

    Article  PubMed  Google Scholar 

  12. Verhulst J, Kramer D, Swann AC, Hale-Richlen B, Beahrs J. The medical alliance: from placebo response to alliance effect. J Nerv Ment Dis. 2013;201(7):546–52.

    Article  PubMed  Google Scholar 

  13. Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, et al. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011;72(12):1669–76.

    Article  PubMed  Google Scholar 

  14. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M. Subject expectations of treatment effectiveness and outcome of treatment with and experimental antidepressant. J Clin Psychiatry. 2004;65:1174–9.

    Article  PubMed  Google Scholar 

  15. Rutherford BR, Marcus SM, Wang P, Sneed JR, Pelton G, Devanand D, et al. A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychol Med. 2013;43(5):975–82.

    Article  CAS  PubMed  Google Scholar 

  16. Sneed JR, Rutherford BR, Rindskopf D, Lane DT, Sackeim HA, Roose SP. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry. 2008;6(1):65–73.

    Article  Google Scholar 

  17. Kocsis JH, Leon AC, Markowitz JC, Manber R, Arnow B, Klein DN, et al. Patient preference as moderator of outcome for chronic form of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry. 2009;70(3):354–61.

    Article  CAS  PubMed  Google Scholar 

  18. Raue PJ, Schulberg HC, Heo M, Klimstra S, Bruce ML. Patients’ depression treatment preferences and initiation, adherence, and outcome: a randomized primary care study. Psychiatr Serv. 2009;60(3):337–43.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Rutherford BR, Tandler J, Brown PJ, Sneed JR, Roose SP. Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome. Am J Geriatr Psychiatry. 2014;22(12):1452–61.

    Article  PubMed  Google Scholar 

  20. McKay KM, Imel ZE, Wampold BE. Psychiatrist effects in the psychopharmacological treatment of depression. J Affect Disord. 2006;92(2–3):287–90.

    Article  PubMed  Google Scholar 

  21. Read J, Gibson K, Cartwright C, Shiels C, Dowrick C, Gabbay M. Understanding the non-pharmacological correlates of self-reported efficacy of antidepressants. Acta Psychiatr Scand. 2015.

  22. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723–33.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159(5):728–37.

    Article  PubMed  Google Scholar 

  24. Fassler M, Meissner K, Schneider A, Linde K. Frequency and circumstances of placebo use in clinical practice—a systematic review of empirical studies. BMC Med. 2010;8:15.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Howick J, Bishop FL, Heneghan C, Wolstenholme J, Stevens S, Hobbs FD, et al. Placebo use in the United Kingdom: results from a national survey of primary care practitioners. PLoS One. 2013;8(3), e58247.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Raz A, Campbell N, Guindi D, Holcroft C, Dery C, Cukier O. Placebos in clinical practice: comparing attitudes, beliefs, and patterns of use between academic psychiatrists and nonpsychiatrists. Can J Psychiatry. 2011;56(4):198–208.

    PubMed  Google Scholar 

  27. Bostick NA, Sade R, Levine MA, Stewart Jr DM, American Medical Association Council on Ethical and Judicial Affairs. Placebo use in clinical practice: report of the American Medical Association Council on Ethical and Judicial Affairs. J Clin Ethics. 2008;19(1):58–61.

    PubMed  Google Scholar 

  28. Mintz DL, Flynn DF. How (not what) to prescribe: nonpharmacologic aspects of psychopharmacology. Psychiatr Clin North Am. 2012;35(1):143–63.

    Article  PubMed  Google Scholar 

  29. Bortz J, Schuster C. Statistik für human- und Sozialwissenschaftler. Berlin: Springer; 2010.

    Book  Google Scholar 

  30. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity. JAMA. 2010;303(1):47–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rutherford BR, Mori S, Sneed JR, Pimontel MA, Roose SP. Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res. 2012;46(6):697–702.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and Treatment. 1 (2a) 1998.

  33. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013;12(3):191–204.

    Article  CAS  PubMed  Google Scholar 

  34. Beidas RS, Edmunds JM, Marcus SC, Kendall PC. Training and consultation to promote implementation of an empirically supported treatment: a randomized trial. Psychiatr Serv. 2012;63(7):660–5.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008;336(7651):999–1003.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Laferton JA, Shedden Mora M, Auer CJ, Moosdorf R, Rief W. Enhancing the efficacy of heart surgery by optimizing patients’ preoperative expectations: study protocol of a randomized controlled trial. Am Heart J. 2013;165(1):1–7.

    Article  PubMed  Google Scholar 

  37. von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer. 2013;13:426.

    Article  Google Scholar 

  38. Murrough JW, Charney DS. Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep. 2012;14(6):643–9.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–41.

    Article  CAS  PubMed  Google Scholar 

  40. King M, Essick C. The geography of antidepressant, antipsychotic, and stimulant utilization in the United States. Health & place. 2013;20:32–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital, Boston, MA, USA

    Sagar Vijapura, Johannes A. C. Laferton & David Wolfe

  2. Austen Riggs Center, Stockbridge, MA, USA

    David Mintz

  3. Beth Israel Deaconess Medical Center, Boston, MA, USA

    Ted J. Kaptchuk

Authors
  1. Sagar Vijapura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes A. C. Laferton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Mintz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ted J. Kaptchuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Wolfe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sagar Vijapura.

Ethics declarations

Disclosures

The authors declare no conflicts of interest.

Funding

This study was not supported by any sources of funding. Dr. Laferton was supported by a fellowship within the Postdoc-Program of the German Academic Exchange Service (DAAD). Ted Kaptchuk was supported by grant #2K24 AT004095 from NCCIH/NIH. For the remaining authors, none was declared.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vijapura, S., Laferton, J.A.C., Mintz, D. et al. Psychiatrists’ Attitudes Toward Non-Pharmacologic Factors Within the Context of Antidepressant Pharmacotherapy. Acad Psychiatry 40, 783–789 (2016). https://doi.org/10.1007/s40596-015-0470-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40596-015-0470-2

Keywords

Search

Navigation